Drug substitution safety should be ensured, says Stockholm Network report
This article was originally published in Scrip
While switching patients from one medicine to another may not be risky in itself, the way in which it is being done raises safety and equity concerns, says a new report, Patient Safety and Comfort– The Challenges of Switching Medicines, from the European think-tank Stockholm Network.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.